| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040150746 |
| P356 | DOI | 10.1038/TPJ.2010.53 |
| P932 | PMC publication ID | 2920066 |
| P698 | PubMed publication ID | 20676065 |
| P5875 | ResearchGate publication ID | 45440918 |
| P50 | author | Roland Eils | Q30004000 |
| Benedikt Brors | Q30004004 | ||
| P2093 | author name string | L Li | |
| F Westermann | |||
| M Fischer | |||
| L Shi | |||
| F Berthold | |||
| D Juraeva | |||
| A Oberthuer | |||
| R D Wolfinger | |||
| Y Kahlert | |||
| P2860 | cites work | Evaluation of reference-based two-color methods for measurement of gene expression ratios using spotted cDNA microarrays. | Q25255703 |
| Quantitative monitoring of gene expression patterns with a complementary DNA microarray | Q27861102 | ||
| Overview of BioCreAtIvE task 1B: normalized gene lists | Q28256968 | ||
| Comparison of the predicted and observed secondary structure of T4 phage lysozyme | Q29398301 | ||
| Diagnosis of multiple cancer types by shrunken centroids of gene expression | Q29615528 | ||
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models | Q30512428 | ||
| Microarray scanner calibration curves: characteristics and implications | Q33219774 | ||
| Fundamentals of experimental design for cDNA microarrays | Q34161168 | ||
| Independence and reproducibility across microarray platforms | Q34413212 | ||
| Forty years of decoding the silence in X-chromosome inactivation | Q34416683 | ||
| Outcome signature genes in breast cancer: is there a unique set? | Q42633433 | ||
| A Simple Generalisation of the Area Under the ROC Curve for Multiple Class Classification Problems | Q55878266 | ||
| Gene Selection for Cancer Classification using Support Vector Machines | Q56535529 | ||
| The use of the area under the ROC curve in the evaluation of machine learning algorithms | Q56594447 | ||
| Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification | Q57270614 | ||
| Expression profiling using cDNA microarrays | Q77895878 | ||
| Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project | Q80238189 | ||
| Ratio-based decisions and the quantitative analysis of cDNA microarray images | Q87383035 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 4 | |
| P921 | main subject | neuroblastoma | Q938205 |
| P304 | page(s) | 258-266 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients | |
| P478 | volume | 10 |
| Q92621325 | 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype |
| Q36911240 | An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. |
| Q39299170 | Analyzing abundance of mRNA molecules with a near-infrared fluorescence technique |
| Q24561405 | Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 |
| Q36441512 | Clinical implementation of RNA signatures for pharmacogenomic decision-making |
| Q35863265 | Comparison of RNA-seq and microarray-based models for clinical endpoint prediction |
| Q38306526 | Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression |
| Q48146623 | Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. |
| Q35158226 | Evaluation of gene expression classification studies: factors associated with classification performance |
| Q34611561 | FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma |
| Q44644664 | Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas |
| Q34100931 | Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 |
| Q36890247 | Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma |
| Q39264816 | Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients |
| Q38294764 | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
| Q92185923 | JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma |
| Q36021061 | MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma |
| Q37686989 | MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma |
| Q47131591 | Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer |
| Q38112822 | Pharmacogenomic Biomarkers for Personalized Medicine |
| Q26866455 | Quality assurance of RNA expression profiling in clinical laboratories |
| Q35070297 | Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression |
| Q38809615 | Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients |
| Q38616603 | Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine |
| Q64106286 | Suppressor gene GRHL1 is associated with prognosis in patients with oesophageal squamous cell carcinoma |
| Q91925404 | Systematic computational identification of prognostic cytogenetic markers in neuroblastoma |
| Q37151755 | The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future |
| Q36437713 | The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells |
| Q30512428 | The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models |
| Q27332436 | Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown |
| Q38817378 | Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma |
| Q37844547 | Transcriptional Profiling to Identify Biomarkers of Disease and Drug Response |
| Q38689375 | Upregulation of LYAR induces neuroblastoma cell proliferation and survival |
| Q42321100 | Wnt signalling is a bi-directional vulnerability of cancer cells |
| Q34059963 | k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction |
| Q38300511 | microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. |
Search more.